Petersohn Walter
Known title: Chief Commercial OfficerCIK: 0001501954
Associated companies
Transaction History
| XRAY | ▲ Buy | Grant | 26 | $0 | 7/8/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 20 | $0 | 4/8/2022 | View on chart |
| XRAY | ▼ Sell | Tax Withholding | 563 | $27K | 3/11/2022 | View on chart |
| XRAY | ▼ Sell | Tax Withholding | 559 | $27K | 3/11/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 1,117 | $54K | 3/11/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 4,104 | $0 | 3/4/2022 | View on chart |
| XRAY | ▼ Sell | Tax Withholding | 576 | $30K | 3/4/2022 | View on chart |
| XRAY | ▼ Sell | Tax Withholding | 625 | $33K | 3/4/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 14 | $0 | 1/14/2022 | View on chart |
| XRAY | ▼ Sell | Open Market | 34,068 | $1.8M | 11/17/2021 | View on chart |
| XRAY | ▲ Buy | Option Exercise | 9,300 | $373K | 11/17/2021 | View on chart |
| XRAY | ▲ Buy | Option Exercise | 5,434 | $260K | 11/17/2021 | View on chart |
| XRAY | ▼ Sell | Open Market | 5,434 | $294K | 11/17/2021 | View on chart |
| XRAY | ▼ Sell | Open Market | 10,747 | $581K | 11/17/2021 | View on chart |
| XRAY | ▲ Buy | Option Exercise | 17,748 | $841K | 11/17/2021 | View on chart |
| XRAY | ▼ Sell | Open Market | 17,748 | $960K | 11/17/2021 | View on chart |
| XRAY | ▼ Sell | Open Market | 9,300 | $503K | 11/17/2021 | View on chart |
| XRAY | ▲ Buy | Option Exercise | 9,134 | $450K | 11/17/2021 | View on chart |
| XRAY | ▼ Sell | Open Market | 9,134 | $494K | 11/17/2021 | View on chart |
| XRAY | ▼ Sell | Tax Withholding | 23,369 | $1.3M | 11/5/2021 | View on chart |
| XRAY | ▲ Buy | Grant | 46,738 | $0 | 11/5/2021 | View on chart |
| XRAY | ▲ Buy | Grant | 13 | $787 | 10/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
XRAY: Earnings, Target Cut, Expansion, Medicare Coverage
XRAY reported its Q2 earnings, prompting analysts to review the company’s outlook. Piper Sandler lowered its target to $12, citing the reset strategy after a new Midwest dental partnership. Meanwhile, the Wellspect unit announced Medicare reimbursement for its Surity urinary portfolio, expanding the company’s product reach. These developments add new layers to XRAY’s growth narrative.
XRAY: Earnings, Target Cut, Expansion, Medicare Coverage. XRAY reported its Q2 earnings, prompting analysts to review the company’s outlook. Piper Sandler lowered its target to $12, citing the reset strategy after a new Midwest dental partnership. Meanwhile, the Wellspect unit announced Medicare reimbursement for its Surity urinary portfolio, expanding the company’s product reach. These developments add new layers to XRAY’s growth narrative.